These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2659280)

  • 1. Chromosomal abnormalities in myeloid hematologic malignancies.
    Rubin CM; Le Beau MM
    Curr Top Microbiol Immunol; 1989; 149():25-34. PubMed ID: 2659280
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome.
    Iurlo A; Mecucci C; Van Orshoven A; Michaux JL; Boogaerts M; Noens L; Bosly A; Louwagie A; Van Den Berghe H
    Cancer Genet Cytogenet; 1989 Dec; 43(2):227-41. PubMed ID: 2598167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isochromosome 21q in hematologic malignancies. Groupe Français de Cytogénétique Hématologique.
    Cancer Genet Cytogenet; 1991 Aug; 55(1):101-5. PubMed ID: 1913595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome abnormalities in secondary myelodysplastic syndromes.
    Bloomfield CD
    Scand J Haematol Suppl; 1986; 45():82-90. PubMed ID: 3515525
    [No Abstract]   [Full Text] [Related]  

  • 5. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
    Larson RA; Le Beau MM; Ratain MJ; Rowley JD
    Blood; 1992 Apr; 79(7):1892-3. PubMed ID: 1558980
    [No Abstract]   [Full Text] [Related]  

  • 6. [Aberrations of chromosome 5 in myeloid malignancies with complex chromosome abnormalities].
    Liu Q; Xu W; Zhu Y; Fan L; Qiu HR; Wang R; Qiao C; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1257-60. PubMed ID: 19099622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
    Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
    Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivative (1;18)(q10;q10): a recurrent and novel unbalanced translocation involving 1q in myeloid disorders.
    Wan TS; Ma SK; Au WY; Chan LC
    Cancer Genet Cytogenet; 2001 Jul; 128(1):35-8. PubMed ID: 11454427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse and cytogenetic evolution in myeloid neoplasms.
    Ertz-Archambault N; Kelemen K
    Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comments on the paper: Microsatellite instability in acute myelocytic leukaemia developed from A-bomb survivors--a biological perspective.
    Plumb M
    Int J Radiat Biol; 2003 May; 79(5):367-70; author reply 371-4. PubMed ID: 12943245
    [No Abstract]   [Full Text] [Related]  

  • 11. Deletions of chromosome 13 in malignant hematologic disorders.
    Johnson DD; Dewald GW; Pierre RV; Letendre L; Silverstein MN
    Cancer Genet Cytogenet; 1985 Nov; 18(3):235-41. PubMed ID: 4052983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to therapy-related myelodysplastic syndromes and acute myeloid leukemia.
    Sill H
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):164-5. PubMed ID: 18391913
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.
    Haase D; Binder C; Bünger J; Fonatsch C; Streubel B; Schnittger S; Griesinger F; Westphal G; Schoch C; Knopp A; Berkovicz D; Krieger O; Wörmann B; Hilgers R; Hallier E; Schulz T
    Leuk Res; 2002 Mar; 26(3):249-54. PubMed ID: 11792413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
    Pedersen-Bjergaard J; Andersen MT; Andersen MK
    Hematology Am Soc Hematol Educ Program; 2007; ():392-7. PubMed ID: 18024656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
    So CC; Ma ES; Wan TS; Yip SF; Chan LC
    Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
    Tefferi A
    Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and susceptibility to therapy-related myeloid neoplasms.
    Leone G; Fianchi L; Pagano L; Voso MT
    Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetics in the investigation of haematological disorders.
    Heim S
    Baillieres Clin Haematol; 1990 Oct; 3(4):921-48. PubMed ID: 2271796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology.
    Paulsson K; Säll T; Fioretos T; Mitelman F; Johansson B
    Cancer Genet Cytogenet; 2001 Oct; 130(2):160-5. PubMed ID: 11675138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related myelodysplastic syndrome in adults with neurofibromatosis.
    Papageorgio C; Seiter K; Feldman EJ
    Leuk Lymphoma; 1999 Feb; 32(5-6):605-8. PubMed ID: 10048435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.